1 / 37

Extrapyramidal diseases

Extrapyramidal diseases. Ⅰ.Formation of basal ganglia. * Corpus striatum:/caudate nucleus neostriatum lentiform/putamen nucleus / nucleusglobus pallidus- paleostriatum * Red nucleus * Substantia nigra * Subthalamic nucleus.

hova
Télécharger la présentation

Extrapyramidal diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Extrapyramidal diseases

  2. Ⅰ.Formation of basal ganglia *Corpus striatum:/caudate nucleus \ neostriatum \lentiform/putamen nucleus / nucleus\globus pallidus- paleostriatum *Red nucleus *Substantia nigra *Subthalamic nucleus

  3. Ⅱ Function Regulation of voluntary motor activity

  4. Ⅲ.clinical features 1.Poverty of movement-hypertonia syndrome position: substantia nigra ;globus pallidus ex : Parkinson’ s disease 2.Increasing of movement-hypotonia syndrome position: caudate nucleus ;putamen nucleus ex : Chorea minor

  5. Parkinson’s Disease

  6. Ⅰ.Definition It is also called paralysis agitans. It is a slowly progressive degeneration disease of the extrapyramidal system. It is characterized by tremor、rigidity、bradykinesia 、abnormal gait and attitude.

  7. Ⅱ.Etiology and Pathogenesis 1.age:>40years old \ 2.Environmental factors :MPTP degeneration of DA neurons 3.Genetic factor / (>50%)

  8. Ⅲ.Pathology and biochemical pathology 1.Pathology (1)Macroscopic changes: no special changes (2)Microscopic changes:widespread cellular degeneration, in substantia nigra, Lewy’s body

  9. 2.Biochemical pathology HVA  tyrosine ↓ dopadecar ↓ decomposition hydroxylase - boxylase ↑MAO,COMT Levo-tyrosine →→→→ Levodopa →→→→ dopamine ↓ ↓↘ Caudate nucleus ←←←←←←←←←↓ ↘ ↙Substantia nigra- Ach ↑ putamen↙ corpus striatum path ↓ nucleus ↓ clinical features

  10. Ⅳ.Clinical Features 1.tremor:usually first occur(60-70%) “pill-rolling” static tremor : the tremor is present when the patient is at rest. When the patient is nervous ,the tremor increase . When the patient move voluntarily or sleep , the tremor is suppressed or disappears entirely.

  11. 2.rigidity Cog-wheel rigidity lead-pipe rigidity

  12. 3.bradykinesia (1).Voluntary movements are reduced (2).Masked face (3).micrographia

  13. 4.Abnormal gait and attitude (1).generalized flexion (2).festinating gait

  14. 5.Other symptoms (1).autonomic disturbances : hypersteatosis:oily face; hyperhidrosis; constipation sphincter disturbance is rare (2).mental symptoms: dementia ;depression (3).dysarthria (4).salivation

  15. Ⅴ.Diagnosis 1.It occurs in old people ,the onset is insidious and progress gradually. 2.Clinical features: tremor 、rigidity 、 bradykinesia、abnormal attitude and gait .

  16. Ⅵ.Differential Diagnosis 1.Secondary parkinson’s disease (Parkinsonism) (1).infection: encephalitis lethargica (2).poisoning: CO,Mn (3).drugs (4).cerebral arteriosclerosis (5).trauma

  17. 2.Others (1).Depression (2).Essential tremor (3).multiple system atrophy: OPCA (4).thyrotoxicosis,alcoholism.

  18. Ⅶ.Treatment 1.Drug treatment (1).anticholinergic drugs Artane 2mg tid po;kemadrin 2.5mg tid po Side-effects: retention of urine; enlarged pupil; hypohidrosis; confusion Contraindications:hypertrophy of prostrate glaucoma

  19. (2).amantadine: 50mg tid po Side-effects :insomnia ; confusion; hallucination Contraindications: epileptic ;hepatic and renal dysfunction

  20. (3)Levodopa L-dopa + dopadecarboxylase inhibitor(DCI) Ex : Madopar ; Sinemet

  21. Side-effects 1.Peripheral side-effects: nauea ;vomiting Postural hypotension; cardiac arrhythmia

  22. 2.Central side-effects (1).motor fluctuation a.End of dose deterioration b.on-off phenomenon (2).dyskinesia a.peak-dose dyskinesia b.Biphasic dyskinesia c.Dystonia (3).mental symptoms:confusion;hallucination

  23. (4)Dopamine receptor stimulant drug: bromocriptine(5)monoamine oxidase B inhibitor(6)COMT inhibitor 2.Surgical treatment 3.Cell transplantation and gene therapy 4.Rehabilitation treatment

  24. Chorea minor

  25. Ⅰ.Definition It is also called Sydenham chorea. It is a common nervous system manifestation of rheumatic fever, it often occurs in children . It is characterized by involuntarily choretic movements、 hypotonia、weakness、 mental symptoms.

  26. Ⅱ Etiology Infection of A hemolytic streptococus

  27. Ⅲ.Clinical features 1.onset:5-15 years old ; F>M; subacute or insidious 2.Choretic movements 3.Muscular tension and power are reduced 4.Mental symptoms 5.Symptoms of rheumatic fever: cardiac disease; fever; WBC↑;rheumatic arthritis; subcutaneous nodule ;blood sedimentation↑;ASO↑

  28. Ⅳ.Diagnosis 1.The age of onset 2.Clinical features 3.Symptoms of rheumatic fever

  29. Ⅴ.Treatment 1.Etiological treatment Penicillin 10-14 days 2.Symptomatic treatment Valii; luminal; chlorpromazine

  30. Hepatolenticular Degeneration (HLD)

  31. Ⅰ.Definition It is also called Wilson’s disease.It is an autosomal recessive inheritant disease caused by copper metabolic disorder. The affected areas mainly are liver and basal ganglia. It is characterized by progressive extrapyramidal symptoms、cirrhosis of the liver 、mental symptoms and K-F ring.

  32. Ⅱ.Etiology and Pathogenesis  Copper  + 2 globulins  ceruloplasmin enzyme   bile,urine,sweet    liver cirrhosis of the liver abnormal  basal ganglia  extrapyramidal deposition symptoms  kidney  renal dysfunction  cornea  K-F ring

  33. Ⅲ.Pathology Degeneration: liver basal ganglia kidney cornea

  34. Ⅳ.Clinical Features 1.nervous symptoms (1)extrapyramidal symptoms: choretic action;tremor;rigidity;bradykinesia (2)mental symptoms:intelligent deficiency 2.symptoms of cirrhosis of the liver 3.K-F ring: 95% 4.others: renal dysfunction

  35. Ⅴ.Investigation 1.ceruloplasmin of serum:↓0.26-0.36g/L 2.copper oxidase activity:↓

  36. Ⅵ.Diagnosis 1.the symptoms of liver and extrapyramidal system. 2.the levels of CP and copper oxidase activity are reduced. 3.K-F ring of cornea 4.positive family history

  37. Ⅶ.Treatment 1.low-copper diet 2.drug treatment first -choice: D-penicillamine 3.symptomatic therapy 4.surgical treatment

More Related